AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6619055
Drug: Piperacillin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (300 mg/kg/day) and tobramycin (7 mg/kg/day) iv
Trial: 30577903
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (Treatment as usual)
Trial: 20175431
Drug: EGCG 270
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 270 mg
Trial: 20175431
Drug: Placebo 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 270 mg
Trial: 20175431
Drug: EGCG 270
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 270 mg + Caffeine 3 mg/kg
Trial: 17471993
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OT)
Trial: 7611390
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein diet (1.62 +/- 0.02 g protein.kg-1.day-1)
Trial: 7611390
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein diet (0.80 +/- 0.02 g protein.kg-1.day-1)
Trial: 2223335
Drug: Flumazenil 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.01 mg kg‐1 administered 5 min after midazolam
Trial: 2223335
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg and 5 mg i.v.
Trial: 28988
Drug: Theophylline-Ephedrine combination
RxNorm normalized name: Theophylline, Ephedrine Hydrochloride, and Phenobarbital Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-Ephedrine combination
Trial: 28988
Drug: Ephedrine-Butabarbital combination
RxNorm normalized name: butabarbital / ephedrine / guaifenesin / theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine-Butabarbital combination
Trial: 28545998
Drug: Aflibercept 4
RxNorm normalized name: aflibercept 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 4 mg/kg
Trial: 28545998
Drug: Aflibercept 1
RxNorm normalized name: aflibercept 114 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 1 mg/kg
Trial: 21465518
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with assessment of bone marrow cytology on day 6
Trial: 16709019
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via convection-enhanced delivery (CED)
Trial: 16709019
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via bolus injection
Trial: 8228934
Drug: Four-dose vaccination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose vaccination scheme starting at month 3 (months 3, 4, 5, and 11)
Trial: 8228934
Drug: Three-dose vaccination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose vaccination scheme starting at birth (months 0, 1, and 6)
Trial: 8228934
Drug: Four-dose vaccination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose vaccination scheme starting at birth (months 0, 1, 2, and 11)
Trial: 2878016
Drug: Combined H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined H1 (diphenhydramine hydrochloride) and H2 (cimetidine) histamine antagonists
Trial: 2878016
Drug: H1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1 antagonist (diphenhydramine hydrochloride) alone
Trial: 28655271
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises
Trial: 28655271
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises (subgroup analysis)
Trial: 25487932
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injection (15 IU to 45 IU, average 31.2±13.9 IU) plus conventional physical therapy
Trial: 25487932
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (PY)
Trial: 20618883
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g cholestyramine powder
Trial: 20618883
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g cholestyramine powder
Trial: 12051571
Drug: Dexloxiglumide 100
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexloxiglumide 100 mg
Trial: 12051571
Drug: Dexloxiglumide 200
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexloxiglumide 200 mg
Trial: 12051571
Drug: Dexloxiglumide 400
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexloxiglumide 400 mg
Trial: 12051571
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of Dexloxiglumide 100 mg
Trial: 12051571
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of Dexloxiglumide 200 mg
Trial: 12051571
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of Dexloxiglumide 400 mg
Trial: 12051571
Drug: Dexloxiglumide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexloxiglumide (all doses)
Trial: 7192147
Drug: Psychoergic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoergic drugs (3 stimulants)
Trial: 6405838
Drug: Postoperative total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative total parenteral nutrition (TPN)
Trial: 6405838
Drug: TPN-5-FU combination
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TPN-5-FU combination
Trial: 22566588
Drug: Ritonavir 50
RxNorm normalized name: ritonavir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 50 mg
Trial: 17645681
Drug: FACT-G based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-G based algorithm
Trial: 10447324
Drug: Sacolene (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacolene (4 g at start and 2 g 4 hourly until cessation of diarrhoea)
Trial: 372858
Drug: gamma-ethylester of
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-ethylester of glutamic acid (25 g)
Trial: 372858
Drug: l-arginine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (25 g)
Trial: 372858
Drug: placebo (physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (physiological solution in identical 500 ml bottles)
Trial: 30371811
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfuse hemoglobin <7 g/dL) in massive burns
Trial: 30371811
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfuse hemoglobin <10 g/dL) in massive burns
Trial: 29734777
Drug: Sunrouge extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunrouge extract containing 11.2 mg anthocyanin and 323.6 mg EGCG
Trial: 29734777
Drug: Yabukita extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yabukita extract containing 322.2 mg EGCG
Trial: 21805328
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (160 mg daily for up to 6 months)
Trial: 17456652
Drug: Dexamethasone 0.0625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.0625 mg/kg
Trial: 17456652
Drug: Dexamethasone 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.125 mg/kg
Trial: 17456652
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg/kg
Trial: 19066382
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg
Trial: 17456652
Drug: Dexamethasone 1.0
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.0 mg/kg
Trial: 9241003
Drug: Brofaromine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (50 mg/day titrated to 150 mg/day)
Trial: 8390340
Drug: Gonadotropin releasing
RxNorm normalized name: Gonadotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin releasing hormone agonist (GnRHA) with low doses of oral estrogen (0.625 mg conjugated estrogen, CE for 6 days/week) and intermittent oral progestogen (10 mg medroxyprogesterone acetate, MPA for 13 days every 4 months)
Trial: 2892259
Drug: Nizatidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg h.s.)
Trial: 26938761
Drug: Regular treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatments (Control)
Trial: 24161413
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (Shanchol™), two doses
Trial: 24161413
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus safe water and hand washing practice
Trial: 19451353
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (402 mg every other day)
Trial: 16756056
Drug: Dalacin C
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dalacin C (original preparation)
Trial: 15531858
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day oral isoflavones
Trial: 15531858
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day oral isoflavones
Trial: 15531858
Drug: 12 mg/day
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/day transdermal isoflavones
Trial: 15531858
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day transdermal isoflavones
Trial: 11745230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI)
Trial: 11745230
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (PEI) alone
Trial: 11745230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with TACE-PEI
Trial: 11745230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with TACE-PEI (for tumors < 2 cm)
Trial: 6363216
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy at intervals of one week
Trial: 6363216
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy at intervals of three weeks
Trial: 31842811
Drug: Vaginal dose
RxNorm normalized name: Product manufactured as vaginal dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dose of radical radiotherapy (using PIBS point system)
Trial: 25243962
Drug: Fufang Biejia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Biejia Ruangan Tablet plus entecavir (Group A, n=56)
Trial: 25243962
Drug: Fufang Biejia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Biejia Ruangan tablet only (Group C, n=55)
Trial: 22007735
Drug: Proprioceptive neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive neuromuscular facilitation (PNF) techniques (rhythmic initiation, dynamic reversion, isotonic combination)
Trial: 10080511
Drug: Once-daily vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily vigabatrin administration
Trial: 10080511
Drug: Twice-daily vigabatrin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily vigabatrin administration
Trial: 1559299
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (GH) for 6 months
Trial: 23361591
Drug: Histidine supplementation
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histidine supplementation (4 g/day for 12 weeks)
Trial: 23361591
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g/day for 12 weeks)
Trial: 19845233
Drug: Alpha tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha tocopherol (525 IU) administered orally at 48 hr, 24 hr, and in the morning prior to coronary procedures
Trial: 19845233
Drug: Placebo compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo compound administered orally at 48 hr, 24 hr, and in the morning prior to coronary procedures
Trial: 8200011
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/day + omega-3 polyunsaturated fatty acids (n3-PUFA)
Trial: 3709642
Drug: sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual isosorbide dinitrate (ISDN) 5 mg
Trial: 22018131
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills
Trial: 24785951
Drug: Hormonal implants
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal implants
Trial: 22730912
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with methylene blue 450 μg/mL and low-power laser
Trial: 22730912
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with wavelength 660 nm, power of 30 mW, fluence of 7.5 J/cm(2)
Trial: 22730912
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg/day for 14 days
Trial: 20970760
Drug: Structured aerobic
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured aerobic exercise regimen (weekly supervised exercise sessions over a 10-week period, including education, warm-up, 30 minutes of aerobic exercise, and cool down, with exercise intensity adjusted to reach a heart rate goal of 60% of the participant's estimated maximal heart rate)
Trial: 16001382
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate 15 mg for depot suspension
Trial: 10601917
Drug: Intravaginally administered
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginally administered moistened misoprostol tablets (800 microg, repeated 24 hours later if needed)
Trial: 10601917
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg) followed by oral misoprostol (400 microg)
Trial: 10601917
Drug: Intravaginally administered
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginally administered moistened misoprostol tablets
Trial: 10601917
Drug: Mifepristone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone and oral misoprostol
Trial: 7793544
Drug: droperidol 1
RxNorm normalized name: droperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 1 mg
Trial: 6157007
Drug: Azathioprine therapy
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine therapy (2 mg/kg body weight daily)
Trial: 28521540
Drug: LMWH/VKA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH/VKA therapy
Trial: 21301819
Drug: MK-0249 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0249 (10 mg)
Trial: 21301819
Drug: MK-0249 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0249 (50 mg)
Trial: 17722823
Drug: Methycobal 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methycobal 250 microg intramuscular injection plus acupuncture at Guanyuan (CV 4), Shenshu (BL 23), Ciliao (BL 32), Huiyang (BL 35), once every day
Trial: 17722823
Drug: Methycobal 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methycobal 250 microg intramuscular injection, once every other day
Trial: 15096240
Drug: Paravertebral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral injection of radio‐opaque dye (10 ml) with co‐administration of 20 ml of local anaesthetics, ventral to the endothoracic fascia
Trial: 15096240
Drug: Paravertebral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral injection of radio‐opaque dye (10 ml) without co‐administration of local anaesthetics, dorsal to the endothoracic fascia
Trial: 30060030
Drug: Oncological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncological therapies
Trial: 25619410
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil (AZL‐M) 40 mg once a day (QD), titrated to 80 mg at week 4, with optional addition of chlorthalidone (CLD) 25 mg QD (weeks 8-22) if required.
Trial: 23789212
Drug: Perilla oil
RxNorm normalized name: Perilla frutescens leaf oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilla oil treatment for 8 weeks
Trial: 21950578
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 400 mg/day
Trial: 19679275
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for FCD type II
Trial: 19679275
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for FCD type II
Trial: 9043731
Drug: Dolasetron mesilate
RxNorm normalized name: Dolasetron mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesilate (12.5, 25, 50, or 100 mg)
Trial: 7911057
Drug: Bunazosin 3
RxNorm normalized name: bunazosin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin 3 mg
Trial: 7911057
Drug: Bunazosin 6
RxNorm normalized name: bunazosin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin 6 mg
Trial: 7911057
Drug: Bunazosin 12
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin 12 mg
Trial: 7911057
Drug: Bunazosin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin (all doses)
Trial: 3328105
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of Prednisone (3960 mg over 54 days, initial dose 200 mg per day)
Trial: 3328105
Drug: Medium doses
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium doses of Prednisone (initial dose 60 mg)
Trial: 24462581
Drug: Disulfiram 250mg
RxNorm normalized name: DISULFIRAM 250MG TAB
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 250mg daily
Trial: 20005081
Drug: Selective serotonin-reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin-reuptake inhibitors (SSRIs) for 52 weeks
Trial: 15354980
Drug: Continuous heparin
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous heparin (250 IU/h, adjusted in 125 IU/h steps)